Search

Your search keyword '"Sikora AE"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Sikora AE" Remove constraint Author: "Sikora AE"
48 results on '"Sikora AE"'

Search Results

1. Development and Validation of Multiplex Assays for Mouse and Human IgG and IgA to Neisseria gonorrhoeae Antigens.

2. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme.

3. [ 99m Tc]Tc-PSMA-T4-Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic.

4. A Critical Need for Research on Gonorrhea Vaccine Acceptability.

5. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates.

6. A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.

7. Neisseria gonorrhoeae MlaA influences gonococcal virulence and membrane vesicle production.

8. Phenotypic MicroArray Screening of Neisseria gonorrhoeae in Chemically Defined Liquid Medium.

9. Reductive Metabolism of Xanthohumol and 8-Prenylnaringenin by the Intestinal Bacterium Eubacterium ramulus.

10. Bioinformatics Workflow for Gonococcal Proteomics.

11. Quantitative Proteomics of the 2016 WHO Neisseria gonorrhoeae Reference Strains Surveys Vaccine Candidates and Antimicrobial Resistance Determinants.

12. PubMLST for Antigen Allele Mining to Inform Development of Gonorrhea Protein-Based Vaccines.

13. Proteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines.

14. Lipid-Modified Azurin of Neisseria gonorrhoeae Is Not Surface Exposed and Does Not Interact With the Nitrite Reductase AniA.

15. Transkingdom network reveals bacterial players associated with cervical cancer gene expression program.

16. SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection.

17. Jizanpeptins, Cyanobacterial Protease Inhibitors from a Symploca sp. Cyanobacterium Collected in the Red Sea.

18. Structural and functional insights into the role of BamD and BamE within the β-barrel assembly machinery in Neisseria gonorrhoeae .

19. Utilization of Vibrio cholerae as a Model Organism to Screen Natural Product Libraries for Identification of New Antibiotics.

20. Methods for Assessments of Collagenolytic Activity of the Vibrio cholerae Extracellular Proteases, Purification of Secreted Collagenase VchC, and Extraction of Type I Collagen from Fish Skin.

22. Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model.

23. Deciphering the Function of New Gonococcal Vaccine Antigens Using Phenotypic Microarrays.

24. Peptide Inhibitors Targeting the Neisseria gonorrhoeae Pivotal Anaerobic Respiration Factor AniA.

25. Detection of bacterial-reactive natural IgM antibodies in desert bighorn sheep populations.

26. Functional and structural studies on the Neisseria gonorrhoeae GmhA, the first enzyme in the glycero-manno-heptose biosynthesis pathways, demonstrate a critical role in lipooligosaccharide synthesis and gonococcal viability.

27. Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism.

28. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization.

29. Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea.

30. Targeting an Essential GTPase Obg for the Development of Broad-Spectrum Antibiotics.

31. Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease.

32. The Neisseria gonorrhoeae Obg protein is an essential ribosome-associated GTPase and a potential drug target.

33. A metalloprotease secreted by the type II secretion system links Vibrio cholerae with collagen.

34. Isolation of Cell Envelopes and Naturally Released Membrane Vesicles of Neisseria gonorrhoeae.

35. Quantitative proteomic analysis of the cell envelopes and native membrane vesicles derived from gram-negative bacteria.

36. The type II secretion pathway in Vibrio cholerae is characterized by growth phase-dependent expression of exoprotein genes and is positively regulated by σE.

37. Quantitative proteomics of the Neisseria gonorrhoeae cell envelope and membrane vesicles for the discovery of potential therapeutic targets.

38. Development of a quantitative assay amenable for high-throughput screening to target the type II secretion system for new treatments against plant-pathogenic bacteria.

39. Proteins secreted via the type II secretion system: smart strategies of Vibrio cholerae to maintain fitness in different ecological niches.

40. Fluorescence microscopy and proteomics to investigate subcellular localization, assembly, and function of the type II secretion system.

41. Antimicrobial rubrolides from a South African species of Synoicum tunicate.

42. Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteases.

43. Cell envelope perturbation induces oxidative stress and changes in iron homeostasis in Vibrio cholerae.

44. Docking and assembly of the type II secretion complex of Vibrio cholerae.

45. Compromised outer membrane integrity in Vibrio cholerae Type II secretion mutants.

46. DNA replication defect in the Escherichia coli cgtA(ts) mutant arising from reduced DnaA levels.

47. The Vibrio harveyi GTPase CgtAV is essential and is associated with the 50S ribosomal subunit.

48. Biochemical properties of the Vibrio harveyi CgtAV GTPase.

Catalog

Books, media, physical & digital resources